ABVX Abivax SA

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Announces Results of its June 6, 2025 Annual General Meeting

PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the “General Meeting”), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax (“Board”).

The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions.

The shareholders have also ratified the appointment of Sylvie Grégoire as Chairman and the appointment of Dominik Höchli, MD as a Board member.

Details of the vote results will be available on the Company’s website ().

*****

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.

Contacts:

Abivax Investor Relations

Patrick Malloy





EN
11/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE

Abivax Announces Pricing of $650M (€554M) Public Offering of American ...

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering ...

 PRESS RELEASE

Abivax announces trading resumption of its ordinary shares on Euronext...

Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from ...

 PRESS RELEASE

Abivax announces temporary trading halt of its ordinary shares on Euro...

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Eu...

 PRESS RELEASE

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) consisting of a public offering of its Amer...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch